Mark L. Bannister
Swansea, WLS, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Increased Intermembrane Space [Ca2+] Drives Mitochondrial Structural Damage in CPVT.
Journal: Circulation research
Published: October 23, 2025
Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
Journal: British journal of pharmacology
Published: July 15, 2021
Identification of an amino-terminus determinant critical for ryanodine receptor/Ca2+ release channel function.
Journal: Cardiovascular research
Published: July 16, 2019
Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia.
Journal: The Journal of physiology
Published: November 02, 2016
Pleiotropic mechanisms of action of perhexiline in heart failure.
Journal: Expert opinion on therapeutic patents
Published: July 26, 2016
Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.
Journal: British journal of pharmacology
Published: February 10, 2016
The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Journal: Circulation research
Published: September 26, 2014
The contribution of hydrophobic residues in the pore-forming region of the ryanodine receptor channel to block by large tetraalkylammonium cations and Shaker B inactivation peptides.
Journal: The Journal of general physiology
Published: August 30, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026